Kessler Topaz Meltzer & Check Alerts Investors About Deadline in APLT Class Action Lawsuit

APLT Class Action Lawsuit Deadline Notification

The law firm of Kessler Topaz Meltzer & Check, LLP has issued a crucial alert for investors concerning a securities fraud class action lawsuit against Applied Therapeutics, Inc. (NASDAQ: APLT). This notice specifically targets those who acquired or purchased securities from Applied Therapeutics between January 3, 2024, and December 2, 2024.

Key Details about the Lawsuit

The class action has been initiated in the United States District Court for the Southern District of New York. The lead plaintiff deadline for this case is set for February 18, 2025. Investors who may have suffered losses during the specified period are encouraged to take notice of these developments.

Allegations Against Applied Therapeutics

The lawsuit alleges that throughout the mentioned class period, the defendants, which include certain executives and representatives of Applied Therapeutics, may have issued statements that were misleading or failed to disclose significant information. Particularly, these allegations concern claims about the company’s adherence to trial protocols and good clinical practices associated with its drug candidate, govorestat. This is critical since any failure to comply with FDA regulations increases the risk of rejection during the New Drug Application process, thus jeopardizing investor interests.

Process for Becoming a Lead Plaintiff

Investors interested in stepping forward as lead plaintiffs in this class action have until February 18, 2025, to express their intent. A lead plaintiff represents the group of investors in guiding the litigation process and is typically the person or an investor group with the most significant financial stake. The lead plaintiff will have the responsibility of selecting legal counsel to represent their interests in the case.

For those who prefer not to serve as a lead plaintiff, remaining as an absent member of the class is an option, and their ability to recover any potential damages will not be affected by this decision.

Contact Information

Kessler Topaz encourages all investors who have incurred substantial losses with Applied Therapeutics to reach out for further clarification and assistance. Interested parties can contact attorney Jonathan Naji at (484) 270-1453 or via email at [email protected] Additional information is also provided on their website.

Conclusion

This lawsuit highlights the importance of due diligence and the risks associated with investments in biotech firms. As the February deadline approaches, investors affected by the alleged misconduct of Applied Therapeutics must act quickly to protect their interests. Staying informed and connected with legal professionals can help in navigating the complexities of such situations.

For comprehensive details regarding the lawsuit and ongoing updates, investors are invited to check the provided links or reach out to Kessler Topaz Meltzer & Check, LLP directly. Taking these steps is essential for ensuring all necessary actions are taken before the impending deadline.